In lymph node positive breast cancer treatment, the challenge is to avoid over treatment and the life-changing impact this can have on a woman’s life, without increasing the risk of node positive breast cancer recurrence.
EndoPredict is an accurate prognostic test for women with breast cancer regardless of lymph node status, reliably guiding lymph node positive breast cancer treatment.
It is the only second generation breast cancer prognostic test validated for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive3-8 – and the first second generation test with level of evidence 1A data.1,2
If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.
Data presented at SABCS 2021 from a prospective randomized phase III study confirms the accuracy and prognostic power of EndoPredict.1
In the analysis of 767 pre- or postmenopausal node positive, clinically high-risk, chemotherapy-treated patients, there was significant dichotomization between high-risk and low-risk groups. The EPclin low-risk group experienced no invasive disease events with a median follow-up of 55 months.
This study represents the first prospective validation in a randomized controlled trial of a second generation breast cancer test, allowing confident decisions when deciding lymph node positive breast cancer treatment.
In node positive subgroups of breast cancer patients, EndoPredict outperforms the first generation Oncotype DX® test and more accurately identifies the true low-risk patients.10 In a direct head-to-head comparison, the EndoPredict low-risk group remains low, within the 10-year risk of <10% distant recurrence specified by guidelines.
57% of patients were categorized as RS low-risk, with a 10-year distant recurrence rate of 19% — outweighing the guideline-based 10% cut-off for chemotherapy indication.
EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.